ArticleSensors (Basel, Switzerland)2026
High-Reliability Signal Quality Validation for Biosignals Using Sensor Fusion and Software Indices.
Article in Sensors (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper proposes a two-stage hybrid framework for biosignal quality validation that produces beat-level or segment-level labels for real-time filtering and offline dataset curation. The framework is quantitatively validated exclusively on ECG data. Its modular architecture is designed to extend to further non-stationary periodic biomedical time-series signals including photoplethysmography (PPG), impedance cardiography (ICG), phonocardiography (PCG), electromyography (EMG), and electroencephalography (EEG) through modality-specific parameter adaptation; however, this broader applicability currently reflects architectural extensibility rather than experimentally validated performance. A prerequisite is synchronized acquisition of the primary biosignal together with inertial motion sensing (IMU/accelerometer) and electrode impedance or lead-off status, with the IMU positioned near the sensing electrodes. The first stage performs sensor-integrity gating to reject intervals corrupted by motion or poor electrode contact. The second stage applies software signal quality indices to the remaining beats, including physiological plausibility constraints (R to R peaks analysis), DTW-based morphological consistency against adaptive templates, frequency domain SNR estimation, and baseline wander quantification. This study systematically evaluates and compares the classification performance of six complementary sensor-level and software-based signal quality assessment methods. When integrated within the proposed hybrid framework, validation against expert-annotated ECG quality labels from 20 healthy participants demonstrates high methodological classification accuracy (98.1%), achieving approximately a 98% F1-score, 99% sensitivity, and 97% specificity. Prospective validation on patient populations with cardiovascular pathology is identified as a necessary step toward clinical deployment. This modular approach improves the reliability of downstream analysis by preventing corrupted data from entering feature extraction and model training pipelines, enabling more stable physiological monitoring in free-living conditions, reducing false alarms in continuous monitoring applications, and generating higher-quality datasets for AI-based diagnostic systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.